Help me with my portfolio I have 100 shares of nams, 29 share jks, 38 shares of ford motor group, 61 shares of lazr and 10 shares of gbxi

Your portfolio is diversified across several sectors, including pharmaceuticals, energy, automotive, and solar industries. However, the significant losses in the net income and diluted EPS of JinkoSolar Holding and Luminar Technologies, along with the negative revenue growth for JinkoSolar Holding, suggest that these stocks may be dragging down the overall performance of your portfolio. Here's a detailed analysis:

1. NewAmsterdam Pharma (NAMS):
   • NAMS has shown strong revenue growth of 32.73% and a significant increase in diluted EPS to $0.46.
   • The company's net income has improved by 61.32%, indicating robust profitability.
   • Despite the positive financial indicators, the stock is currently undervalued with a price-to-book ratio of 3.88 and a price-to-sales ratio of 217.09, which may present a buying opportunity.

2. JinkoSolar Holding (JKS):
   • JKS has experienced a substantial decline in net income by 104.94% and a significant drop in diluted EPS to -$0.07.
   • The company's revenue has decreased by 21.78%, which could be a concern for investors.
   • JKS has a low price-to-earnings ratio of 4.67, which may suggest that the market has low growth expectations. However, the recent increase in its relative strength (RS) rating to 89 could indicate a potential turnaround.

3. Ford Motor (F):
   • Ford Motor's net income has decreased by 9.08%, but the diluted EPS has increased by 39.39% to $0.46.
   • The company's revenue has grown by 6.35%, and it has a positive free cash flow of $6.78 billion.
   • Ford Motor has a low price-to-book ratio of 0.96 and a price-to-sales ratio of 0.23, indicating a potentially undervalued stock.

4. Luminar Technologies (LAZR):
   • LAZR's net income has improved by 7.86%, but the diluted EPS has decreased to -$0.29.
   • The company's revenue has only increased by 1.57%, which may not be satisfactory for investors.
   • LAZR has a high price-to-earnings ratio of 6.05, which could suggest that the market is expecting high growth.

5. NewAmsterdam Pharma (NAMS):
   • NAMS does not currently pay dividends.

In conclusion, while NewAmsterdam Pharma and Ford Motor show promising financial indicators, JinkoSolar Holding and Luminar Technologies present challenges. You may consider holding your positions in NAMS and F, but closely monitor the performance of JKS and LAZR. If the financial performance of JKS and LAZR does not improve, you may want to consider reducing your exposure to these stocks. Additionally, the recent positive developments in NAMS and the potential undervaluation of Ford Motor suggest that these could be good long-term investments. However, it's important to conduct your own due diligence and consider your risk tolerance before making any investment decisions.